Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UnipharDUB:UPR +0.90%71 EV-to-EBIT is 17.67 as of Jul. 27, 2026, which is 15% above its 10-year median of 15.32. GuruFocus rates DUB:UPR with a GF Score™ of 71/100 and a GF Value™ of €3.65 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 94 Medical Distribution companies, Uniphar ranks worse than 73.4% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Uniphar's Enterprise Value is €1,487 Mil.
Uniphar's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €84 Mil. Therefore, Uniphar's EV-to-EBIT for today is 17.67.
The historical rank and industry rank for Uniphar's EV-to-EBIT or its related term are showing as below:
DUB:UPR'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7.47 Med: 15.32 Max: 34.28
Current: 17.67
During the past 10 years, the highest EV-to-EBIT of Uniphar was 34.28. The lowest was 7.47. And the median was 15.32.
DUB:UPR's EV-to-EBIT is ranked worse than 73.4% of 94
companies
in the Medical Distribution industry
Industry Median: 11.53
vs DUB:UPR: 17.67
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Uniphar's Enterprise Value for the quarter that ended in Dec. 2025 was €1,243 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Uniphar's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Uniphar EV-to-EBIT Related Terms
Uniphar EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Uniphar's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Uniphar's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Uniphar's EV-to-EBIT falls into.
Uniphar's current Enterprise Value is €1,487 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Uniphar's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Uniphar (DUB:UPR) has a EV-to-EBIT of 17.67 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Uniphar and its competitors. This is 15% above median its historical median of 15.32. Over the past decade, Uniphar's EV-to-EBIT has ranged from 7.47 to 34.28. According to the industry distribution chart, Uniphar ranks #69 out of 94 companies in the Medical Distribution industry, placing it in the top 73.4%.
Is Uniphar's EV-to-EBIT too high?
Uniphar's current EV-to-EBIT of 17.67 is 15% above median its 10-year median of 15.32. Over the past 10 years, this metric has ranged from a low of 7.47 to a high of 34.28. The Medical Distribution industry median EV-to-EBIT is 11.53. Uniphar's value of 17.67 is 53.3% above this industry median. Based on the distribution chart, Uniphar ranks #69 out of 94 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Uniphar has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Uniphar ranks #69 out of 94 companies for EV-to-EBIT. This places Uniphar in the lower half of its industry. The industry median EV-to-EBIT is 11.53. Uniphar's value of 17.67 is 53.3% above this benchmark. Historically, Uniphar's own EV-to-EBIT has ranged from 7.47 to 34.28 over the past decade. While the company's 10-year median is 15.32 vs. the industry median of 11.53, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.53, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current EV-to-EBIT of 17.67 is 53.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current EV-to-EBIT is 17.67, which is 15% above median its own 10-year median of 15.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.65, compared to a current price of €4.46 — trading 22.2% above its estimated fair value. The current EV-to-EBIT is 17.67, which is 15% above median its 10-year median of 15.32 and 53.3% above the Medical Distribution industry median of 11.53. Uniphar's overall GF Score™ is 71/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current EV-to-EBIT is 17.67 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.46 is trading 22.2% above its estimated GF Value™ of €3.65.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for DUB:UPR:
EV-to-EBIT: 17.67 (15% above median its 10-year median of 15.32)
GF Value™: €3.65 vs. price of €4.46 (22.2% above fair value)
Industry Position: 53.3% above the Medical Distribution median (#69 of 94)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
71GF Score
Get the complete analysis for DUB:UPR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
